Company Overview and News

2
Nabriva Therapeutics to Present Data at ECCMID Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia

2018-04-13 globenewswire
DUBLIN, Ireland, April 13, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics Plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that it will present data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking place in Madrid, Spain from April 21-24, 2018.

2
NBRV / Nabriva Therapeutics AG / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-04-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _ )* Nabriva Therapeutics plc (Name of Issuer) Common Stock (Title of Class of Securities) G63637105 (CUSIP Number)

4
NBRV / Nabriva Therapeutics AG / Wellington Management Group LLP - SEC SCHEDULE 13G (Passive Investment)

2018-04-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. _ )* Nabriva Therapeutics plc (Name of Issuer) Common Stock (Title of Class of Securities) G63637105 (CUSIP Number)

14
NBRV / Nabriva Therapeutics AG S-3/A

2018-04-09 sec.gov
Table of Contents As filed with the Securities and Exchange Commission on April 9, 2018

1
Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer

2018-04-05 globenewswire
CHESTERBROOK, Pa., April 05, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that President and Chief Executive Officer Maxine Gowen, Ph.D., will retire on October 1, 2018. The Board of Directors has selected Carrie L. Bourdow, who currently serves as Trevena’s Executive Vice President and Chief Operating Officer, to be the Company’s next President and Chief Executive Officer, effective October 1, 2018.

 
Paratek's (PRTK) NDAs for Omadacycline Get Priority Review

2018-04-05 zacks
Paratek Pharmaceuticals, Inc. (PRTK - Free Report) announced that the FDA has accepted two new drug applications (NDAs), seeking approval of its antibiotic candidate, omadacycline. The NDAs were granted priority review, thus speeding up the review process. A decision is expected in October 2018.

 
Week In Review: WuXi AppTec Plans $910 Million Shanghai IPO

2018-04-01 seekingalpha
WuXi AppTec announced a $910 million IPO on the Shanghai exchange for the company's core small-molecule CRO business. China regulators approved WuXi's prospectus in a short seven weeks, indicating that they are very eager to list the company, China's largest CRO, on a domestic exchange. Two years ago, WuXi AppTec de-listed from the New York Exchange in a $3.3 billion privatization led by Dr. Ge Li, the company's Founder and Chairman, and backed by AllyBridge.

3
Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia.

2
 
BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

2018-03-27 reuters
* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

 
Paratek: A Review Of Progress And Preview Of 2018

2018-03-21 seekingalpha
Paratek Pharmaceuticals (PRTK) is a biopharmaceutical company making steady progress towards approval of its novel tetracycline antibiotic, omadacycline. Omadacycline produced impressive results in three phase 3 studies, the results of which, coupled with other progress, can no longer be seen in the share price.

 
Nabriva Therapeutics Appoints Jennifer Schranz, M.D., as Chief Medical Officer

2018-03-21 globenewswire
DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Jennifer Schranz, M.D., as Chief Medical Officer.

2
NBRV / Nabriva Therapeutics AG S-3

2018-03-16 sec.gov
Table of Contents As filed with the Securities and Exchange Commission on March 16, 2018

 
NBRV / Nabriva Therapeutics AG 424B5 (Prospectus)

2018-03-16 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS PROSPECTUS SUPPLEMENT TABLE OF CONTENTS

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 62957M104